Kerri Fitzgerald

DocwireNews

A study published in Cancer Science observed that isatuximab monotherapy was an effective and well-tolerated treatment for relapsed/refractory multiple myeloma (MM).The open&#8208;label, single&#8208;arm, multicenter, phase I/II trial assessed the tolerability, safety, and efficacy of isatuximab monotherapy in a cohort of Japanese patients with heavily pretreated relapsed/refractory MM.In phase I of the trial, patients were sequentially assigned to receive isatuximab once weekly in cycle one and every two weeks in subsequent cycles. Cohort one (n=3) received isatuximab 10 mg/kg, and cohort two (n=5) received isatuximab 20 mg/kg. No dose&#8208;limiting toxicities occurred, so the recommended phase II dose was isatuximab 20 mg/kg (n=28).The safety profile of isatuximab was consistent with previously safety data associated with this therapy. The most common adverse events were infusion reactions (42.9%; n=12/28), all of which were grade 1/2 and generally occurred during the first infusion.The overall response rate with isatuximab 20 mg/kg was 36.4% (n=12/33). Patients with high&#8208;risk cytogenetic abnormalities had comparable response rates. In phase II, the median progression&#8208;free survival was 4.7 months (95% confidence interval, 3.75 to not reached), while the median overall survival was not reached.&ldquo;Isatuximab monotherapy was well tolerated and effective in patients with heavily pretreated relapsed/refractory MM, including high&#8208;risk cytogenetic patients,&rdquo; the authors concluded.

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Isatuximab Monotherapy Demonstrates Efficacy in Relapsed/Refractory Multiple Myeloma

Oncology

A study published in Cancer Science observed that isatuximab monotherapy was an effective and well-tolerated treatment for relapsed/refractory multiple myeloma (MM). ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe